Your browser doesn't support javascript.
loading
Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson's disease.
Sauerbier, Anna; Herberg, Johanna; Stopic, Vasilija; Loehrer, Philipp A; Ashkan, Keyoumars; Rizos, Alexandra; Jost, Stefanie T; Petry-Schmelzer, Jan Niklas; Gronostay, Alexandra; Schneider, Christian; Visser-Vandewalle, Veerle; Evans, Julian; Nimsky, Christopher; Fink, Gereon R; Antonini, Angelo; Martinez-Martin, Pablo; Silverdale, Monty; Weintraub, Daniel; Schrag, Anette; Ray Chaudhuri, K; Timmermann, Lars; Dafsari, Haidar S.
Afiliação
  • Sauerbier A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany. anna.sauerbier@uk-koeln.de.
  • Herberg J; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. anna.sauerbier@uk-koeln.de.
  • Stopic V; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
  • Loehrer PA; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
  • Ashkan K; Department of Neurology, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
  • Rizos A; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.
  • Jost ST; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.
  • Petry-Schmelzer JN; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
  • Gronostay A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
  • Schneider C; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
  • Visser-Vandewalle V; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
  • Evans J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Stereotactic and Functional Neurosurgery, Cologne, Germany.
  • Nimsky C; Department of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Greater Manchester, UK.
  • Fink GR; Department of Neurosurgery, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
  • Antonini A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
  • Martinez-Martin P; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Jülich, Jülich, Germany.
  • Silverdale M; Parkinson and Movement Disorders Unit, Department of Neurosciences (DNS), University of Padua, Padova, Italy.
  • Weintraub D; Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
  • Schrag A; Department of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Greater Manchester, UK.
  • Ray Chaudhuri K; Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-2676, USA.
  • Timmermann L; Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, University College London, London, UK.
  • Dafsari HS; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
NPJ Parkinsons Dis ; 10(1): 114, 2024 Jun 08.
Article em En | MEDLINE | ID: mdl-38851717
ABSTRACT
The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson's disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In this prospective, open-label, multicentre study, we assessed patients with anxiety undergoing STN-DBS for PD preoperatively and at 6-month follow-up postoperatively. We assessed the Hospital Anxiety and Depression Scale (HADS-anxiety and depression subscales), Unified PD Rating Scale-motor examination, Scales for Outcomes in PD-motor (SCOPA-M)-activities of daily living (ADL) and -motor complications, Non-Motor Symptom Scale (NMSS), PDQuestionnaire-8 (PDQ-8), and levodopa-equivalent daily dose. We tested changes at follow-up with Wilcoxon signed-rank test and corrected for multiple comparisons (Bonferroni method). We identified patients with a clinically relevant anxiety improvement of anxiety based on a designated threshold of ½ standard deviation of baseline HADS-anxiety. Moreover, we investigated predictors of HADS-anxiety changes with correlations and linear regressions. We included 50 patients with clinically relevant baseline anxiety (i.e., HADS-anxiety ≥ 8) aged 63.1 years ± 8.3 with 10.4 years ± 4.5 PD duration. HADS-anxiety improved significantly at 6-month follow-up as 80% of our cohort experienced clinically relevant anxiety improvement. In predictor analyses, worse baseline SCOPA-ADL and NMSS-urinary domain were associated with greater HADS-anxiety improvements. HADS-anxiety and PDQ-8 changes correlated moderately. Worse preoperative ADL and urinary symptoms predicted favourable postoperative anxiety outcome, which in turn was directly proportionate to greater QoL improvement. This study highlights the importance of detailed anxiety assessments alongside other non-motor and motor symptoms when advising and monitoring patients undergoing STN-DBS for PD.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article